CTLA4 and non-small cell lung carcinoma: Other innovative therapies include treatment with QL1706, a dual-function antibody targeting both CTLA-4 and PD-1, currently being studied in the DUBHE-L-304 (NCT05487391) phase III trial, which also assesses its combination with chemotherapy in resected stage II–IIIB NSCLC patients [43].